Skip to content
Review Open access

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Sep 2026 · Brain and Behavior · Vol 16 · 0 citations · 16 references
Medicine

Abstract

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology, or distinct cognitive phenotypes. However, available evidence remains limited, fragmented, and methodologically heterogeneous.

Read PDF

Similar papers

Editorial Open access Aug 2026

Beyond Amyloid: Hippocampal Atrophy as a Prognostic Marker in Amyloid-Negative Subjective Cognitive Decline

The emergence of blood-based biomarkers (BBMs) has transformed the diagnosis of Alzheimer’s disease (AD). 1,2 Plasma phosphorylated tau, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) have demonstrated remarkable accuracy in detecting amyloid pathology and predicting disease progression acr...

H. Kwon, Seong-Ho Koh · 0 citations
Open access Sep 2026

Post mortem MRI of cholinergic white matter pathways across neurodegenerative diseases

Cholinergic white matter pathway degeneration is central in Alzheimer's disease and Lewy body disease and can be assessed in vivo using magnetic resonance imaging proxies, but neuropathological validation is limited.

F. López-González, M. Němý, C. Jerele et al. · 0 citations
Open access Sep 2026

Dopaminergic‐ and Cholinergic‐Related Structural MRI Patterns Across Cognitive Subtypes of Parkinson's Disease With Mild Cognitive Impairment

The dual syndrome hypothesis distinguishes frontostriatal and posterior cortical cognitive subtypes in Parkinson's disease with mild cognitive impairment (PD‐MCI), which are associated with distinct cognitive profiles and different risks of dementia.

Xue-Qin Bai, Hao-Xin Chen, Qiu-Yue Li et al. · 0 citations
Review Sep 2026

Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.

A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...

L. Grinberg, M. Murray · 0 citations
Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance, and NfL levels were elevated across diseases, and total α‐synuclein levels were associated with tau positivity.

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.